Miaa-376 May 2026

| Quarter | Feature | Impact | |--------|----------|--------| | Q3 2026 | Explainability Dashboard v2 – customizable visual causal pathways. | Faster stakeholder buy‑in. | | Q4 2026 | Edge‑Optimized CARE – lightweight inference on IoT devices. | Real‑time insights at the source. | | Q1 2027 | Auto‑ML for Knowledge Graph Enrichment – self‑learning schema extensions. | Reduce manual curation effort. | | Q2 2027 | MIAA‑376 Marketplace – community‑contributed modules, datasets, and best‑practice recipes. | Grow ecosystem, accelerate adoption. |

MIAA‑376 is open‑source at its core (the CARE Core under Apache 2.0) while the enterprise runtime is offered under a flexible subscription model. We actively encourage contributions—bug reports, new connectors, or novel reasoning primitives—and host quarterly Insight Hackathons where participants build domain‑specific solutions on top of the platform.

In the tech or manufacturing sectors, "MIAA-376" could function as an internal project code or product model number. For instance: MIAA-376

Real-World Examples:

Conclusion: Without insider knowledge or leaks, this interpretation is challenging to confirm. However, corporations occasionally hint at such codes in patents or job listings. In the tech or manufacturing sectors, "MIAA-376" could

MIAA‑376 implements a continuous learning loop:

Because the loop is user‑in‑the‑middle, the system improves not just statistically but also semantically. Real-World Examples:

| Phase | Design | Population | Primary Endpoint | Status | |-------|--------|------------|------------------|--------| | Phase I (dose‑escalation) | 3 + 3 design, oral daily dosing | Advanced solid tumors refractory to standard therapy (incl. melanoma, NSCLC, colorectal) | Safety, MTD, PK/PD, Preliminary efficacy (RECIST v1.1) | IND filed (April 2024). Expected start Q3 2025. | | Phase Ib (combo) | Fixed dose of MIAA‑376 + anti‑PD‑1 (pembrolizumab) | Metastatic melanoma with prior anti‑PD‑1 failure | ORR, DOR, Immune biomarkers | Protocol development underway. | | Phase II (biomarker‑enriched) | Randomized 1:1 MIAA‑376 + PD‑1 vs. PD‑1 alone | BRAF‑wildtype, high MIA‑A expression (RNA‑seq cut‑off) | PFS, OS, Biomarker correlation (MIA‑A serum levels) | Planned for 2027 pending Phase I read‑out. |

**Key Biomarker: Elevated circulating MIA‑A (ELISA > 250 ng/mL) correlates with poor response to checkpoint blockade. Patients with high baseline MIA‑A may derive the greatest benefit from MIAA‑376.